Retail investors in Canadian cannabis are ‘buying air,’ analyst says 


Canadian marijuana shares are overvalued, as a result of they’re nonetheless simply commodities, Sean Stiefel, founder and hashish portfolio supervisor of Navy Capital, advised CNBC on Wednesday.

“We expect issues have gotten a bit bit foolish,” Stiefel mentioned on CNBC’s “Closing Bell.” “Valuations now have actually gotten forward of themselves, and the retail investor right here is now shopping for air, successfully.”

Stiefel’s feedback come amid volatility in medical marijuana firm Tilray’s inventory. The corporate on Tuesday introduced that the Drug Enforcement Company authorized its efforts to export a cannabinoid research drug into america from Canada for a medical trial.

In a wild day of buying and selling on Wednesday, Tilray gave up a 90 % one-day surge and turned unfavorable, earlier than ending the day up 38 %, its finest day since going public in July. The inventory was halted 5 occasions on Wednesday by the Nasdaq for volatility.

Latest beneficial properties in marijuana shares have additionally been fueled by funding from alcohol and beverage corporations, and hypothesis of merger and acquisition exercise to come back. However Stiefel says Canadian marijuana corporations are “basically simply commodity producers,” that means they lack the mental property from branding that’s so beneficial to shopper merchandise corporations.

On Oct. 17, when the leisure marijuana market opens in Canada, “all that is going to be out there’s flower and low-concentrate oil. There is no branding,” Stiefel mentioned.

“The concept any person goes to spend $5 billion, $10 billion, $20 billion is foolish. There may be significantly better property, significantly better [intellectual property] outdoors of Canada — within the U.S., in Israel. You’re spending rather a lot for air,” he added.

Stiefel says Canadian corporations might dominate in marijuana provide, however in branding, the U.S. will finally lead.

“The manufacturers that emanate from California are going to be the manufacturers that actually do dominate,” Stiefel mentioned. “We expect manufacturers are going to emanate from the U.S., we predict distribution might theoretically emanate from Canada, however at these costs, you are actually not getting a lot bang in your buck up there.”

In response to Stiefel, “it’s totally arduous to say” whether or not the sector as a complete is overvalued, however Canada definitely is.

“All you want is the licensing, the manufacturing and the uncooked substances. There’s not an amazing quantity of [research and development], except possibly Cover and CannTrust, up in Canada that actually differentiates anybody up there, versus the plethora of $100 million or much less corporations sitting in California,” Stiefel mentioned.

Earlier on Wednesday, Wall Road dealer Jon Najarian warned valuations within the marijuana sector, together with Tilray’s, are getting uncontrolled.

“That is simply silly time. I can not imagine the valuations at this stage,” the Investitute co-founder mentioned in an interview on Wednesday.

The dealer mentioned he rode a few of Tilray’s transfer greater after its IPO, however is not at present lengthy the shares.

Carter Value, the Cornerstone Macro technical analyst who final week referred to as a surge in pot shares, says he thinks Tilray has topped out for the foreseeable future — and will even reverse.

“The excessive of at present, does that stand for a very long time? It is my hunch that it does,” Value mentioned Wednesday on CNBC’s “Quick Cash.”

“Pot shares basically, it is a long term. We’ve talked about that, that is just the start. However this specific inventory on this specific day has all of the indications of a key reversal, a nasty shut. The excessive ought to be in for a very long time,” Value mentioned.

Tilray hit an intraday excessive of $300 per share on Wednesday earlier than paring a few of these beneficial properties to shut up 38 % at $214.06. Tilray has skyrocketed greater than 800 % because it started buying and selling on the Nasdaq at $23.05 per share in July.